KAPOLEI, HI, October 23, 2024 — TruTag Technologies, Inc. today announced the launch of a new business unit, SiCare Bio, which is focused on enabling the next generation of precision nano-therapeutics.
Over the last decade, TruTag has become the global leader in the manufacture of high-precision, bio- compatible nanoporous silica (nPSi). SiCare Bio now will leverage this manufacturing expertise to offer a novel drug delivery platform to the pharmaceutical industry. SiCare Bio’s platform has two primary applications – targeted-drug delivery via its nPSi nanoparticles and extended-release drug delivery via its nPSi microparticles. SiCare Bio is already working with three pharmaceutical companies and expects to have a number of additional companies onboarded by the end of the year.
TruTag CEO Barry McDonogh said, “Our nPSi particles are highly differentiated versus other forms of commodity mesoporous silica being used in drug delivery today. Our proprietary processes developed over the last ten years enable superior loading efficiency and smoother payload expression compared to alternative silica-based platforms. There has been significant interest in our solution already, and we currently are engaged in development programs with leading pharmaceutical companies. Our goal is to work with these development partners to bring safe and efficacious therapies to market.”
The SiCare Bio business unit will remain wholly owned by TruTag. To learn more about SiCare Bio, go to SiCareBio.com
About SiCare Bio
SiCare Bio is the global leader in the manufacture of high-precision, bio-compatible nanoporous silica (nPSi). Our nPSi particles are configured for the precision delivery of a range of therapeutics and offer a safe, programmable platform for the loading and sustained release of therapeutic payloads. Applications include extended release drug delivery and targeted drug delivery. A division of TruTag Technologies.
About TruTag Technologies
TruTag Technologies, Inc. is the leading manufacturer of high precision, nano-porous silicon dioxide (pSi) particles and has developed a digital health technology platform that is utilized by pharmaceutical companies for safeguarding patients and improving patient outcomes. TruTag’s pSi particles are utilized in an array of applications – from enabling pharmaceutical companies to digitize medicines, to developing new controlled-drug delivery therapies. Learn more at TruTags.com.
Media Contact:
SiCare Bio: info@sicarebio.com